March 22, 2022 02:14 PM EDT

Generic drug industry calls on FTC to dig into monopsony power among buyers, PBMs

Zachary Brennan

Senior Editor

The generic drug industry group is calling on the Federal Trade Commission to crack down on monopsony power — or undue market control — exercised by drug …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Generic drug industry calls on FTC to dig into monopsony power among buyers, PBMs

Zachary Brennan

Senior Editor

Sign up to read this article for free.

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Updated: Patient dies in Rocket gene therapy trial, which is put on clinical hold by FDA

Lilly to buy non-opioid pain biotech SiteOne for up to $1B

RFK Jr. ends annual Covid vaccine recommendations for kids, pregnant women

Investors pump $130M into protein degrader startup GlycoEra

Prothena’s amyloidosis drug flops again, spending and staff cuts are on the way

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Gener­ic drug in­dus­try calls on FTC to dig in­to monop­sony pow­er among buy­ers, PBMs

Senior Editor

Sign up to read this article for free.

Autonomy Bio Inc.

San Francisco, CA 94107, USA

Generic drug industry calls on FTC to dig into monopsony power among buyers, PBMs